PharmaSGP Holding SE (PSG) AI Stock Analysis

• Market Cap: €376.80M
• Dividend Yield: 0.16%
• Average Volume (3M): 10.12K
• Price to Earnings (P/E): 18.7
• Beta (1Y): -0.16
• Revenue Growth: 13.80%
• EPS Growth: 10.94%
• Country: DE
• Employees: 91
• Sector: Healthcare
• Sector Strength: 47
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 12,000,000
• 10 Day Avg. Volume: 7,200
• 30 Day Avg. Volume: 10,124
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €32.00
• Price Target Upside: 5.96% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 75 Outperform
• Price Target: €32.00 ▲(5.96% Upside)

PharmaSGP Holding SE receives a solid score driven by strong financial performance and positive technical momentum. The company's effective operational efficiency and attractive dividend yield enhance its investment appeal. While valuation metrics are reasonable, the slight decline in cash flow growth is a minor concern. The lack of significant earnings call data or corporate events does not impact the score.

PharmaSGP Holding SE Business Overview & Revenue Model

Company Description

PharmaSGP Holding SE (PSG) is a leading consumer health company based in Germany, specializing in the development and marketing of over-the-counter (OTC) pharmaceutical products. The company focuses on herbal medicines and dietary supplements, targeting therapeutic areas such as pain management, allergies, and dermatological conditions. PharmaSGP's portfolio includes well-known brands that are distributed across various European markets.

How the Company Makes Money

PharmaSGP Holding SE generates revenue primarily through the sale of its OTC pharmaceutical products and dietary supplements. The company markets its products directly to consumers and through partnerships with pharmacies and healthcare providers across Europe. Revenue streams include sales from its proprietary brands, licensing agreements, and strategic collaborations for distribution. PharmaSGP's focus on innovation and expanding its product range contributes to its ability to capture a significant market share in the consumer health sector. Additionally, the company's emphasis on natural and herbal ingredients allows it to capitalize on the growing demand for alternative and complementary medicine.

PharmaSGP Holding SE Financial Statement Overview

Summary

PharmaSGP Holding SE exhibits strong financial health with consistent revenue and profit growth. Key strengths include a robust gross profit margin of 90.55% and a net profit margin of 16.14%. The company also demonstrates effective cost management with strong EBIT and EBITDA margins. However, the slight decline in free cash flow growth suggests a need for improved cash flow management.

Income Statement

PharmaSGP Holding SE shows consistent revenue and profit growth, highlighting strong operational performance. The TTM (Trailing-Twelve-Months) gross profit margin is robust at 90.55%, and the net profit margin is healthy at 16.14%. The company has demonstrated a solid revenue growth rate of 2.75% from the previous year. EBIT and EBITDA margins are strong at 23.05% and 32.29%, respectively, indicating effective cost management and operational efficiency.

Balance Sheet

The company maintains a strong equity position with an improved debt-to-equity ratio of 0.02, showcasing low leverage and financial stability. The return on equity is impressive at 53.76%, reflecting efficient use of equity capital. However, the equity ratio stands at 31.03%, suggesting room for improvement in asset financing through equity.

Cash Flow

PharmaSGP's cash flow generation is strong, with a positive free cash flow growth rate of -11.77% in the latest period, indicating a slight decline. The operating cash flow to net income ratio is 1.13, and the free cash flow to net income ratio is 1.05, both reflecting solid cash conversion and liquidity management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	122.10M	118.84M	101.10M	85.82M	65.34M	63.25M
Gross Profit	110.56M	107.99M	91.64M	76.79M	58.86M	57.04M
EBITDA	39.43M	39.59M	35.87M	27.18M	18.49M	14.74M
Net Income	19.71M	19.54M	16.40M	11.95M	10.69M	10.64M
Balance Sheet
Total Assets	118.18M	114.27M	131.30M	129.11M	115.26M	24.94M
Cash, Cash Equivalents and Short-Term Investments	29.32M	26.49M	40.77M	33.88M	20.82M	8.00M
Total Debt	860.00K	963.00K	73.98M	8.88M	85.19M	384.00K
Total Liabilities	81.51M	82.31M	91.55M	98.01M	93.06M	13.44M
Stockholders Equity	36.67M	31.96M	39.75M	31.10M	22.20M	11.51M
Cash Flow
Free Cash Flow	20.65M	23.40M	25.77M	23.93M	-71.22M	14.56M
Operating Cash Flow	22.18M	24.88M	26.64M	24.71M	12.24M	15.46M
Investing Cash Flow	-1.53M	-1.47M	-866.00K	-787.00K	-83.46M	-898.00K
Financing Cash Flow	-37.59M	-37.68M	-17.65M	-12.11M	84.04M	-95.03M

PharmaSGP Holding SE Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 30.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:PSG, the sentiment is Positive. The current price of 30.2 is above the 20-day moving average (MA) of 29.35, above the 50-day MA of 28.88, and above the 200-day MA of 26.38, indicating a bullish trend. The MACD of 0.49 indicates Negative momentum. The RSI at 62.16 is Neutral, neither overbought nor oversold. The STOCH value of 88.10 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:PSG.

PharmaSGP Holding SE Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PSG	75 Outperform	€376.80M	18.74	48.46%	0.16%	13.80%	10.94%
Sector *	51 Neutral	$7.81B	-0.22	-40.01%	2.29%	21.48%	-2.11%
MEDOF	―	$447.33M	21.44	3.56%	―	―	―
SBX	―	€17.78M	―		―	―	―
93M1	73 Outperform	€76.85M	2.40	12.12%	6.78%	-15.43%	8.45%
M12	69 Neutral	€245.43M	15.22	14.61%	3.75%	7.23%	58.37%
APPH	58 Neutral	€92.23M	139.31	2.09%	―	27.42%	―